fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Testing a immunological drug as a new treatment for early type 1 diabetes

Written by | 29 Jan 2023

A large clinical study is now beginning on an approved drug for treating psoriasis. The drug will be tested on patients who were recently diagnosed with type 1… read more.

Suffering from psoriasis? Blame this trio of proteins

Written by | 27 Nov 2021

New study shows there may be a way to help even more psoriasis patients. About 7.5 million Americans suffer from psoriasis, an autoimmune disease that shows up as… read more.

Safety analysis of biologics and highlighting vaccine hesitancy: real-world data shines a light on the impact of COVID-19 on psoriasis patients

Written by | 11 Oct 2021

Real-world data looking at biologic treatment and vaccine hesitancy in psoriasis patients is being presented at EADV’s 30th Congress. The findings of two studies are helping to advance… read more.

Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis

Written by | 8 Jun 2021

Novartis,has announced the FDA has approved Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for… read more.

Otezla significantly improved measures of disease severity in adults with mild-to-moderate plaque psoriasis – Amgen

Written by | 29 Apr 2021

Amgen announced Otezla (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area (BSA) affected by the disease , according… read more.

Health Canada approves Taltz for pediatric patients with plaque psoriasis – Eli Lilly

Written by | 2 Apr 2021

Health Canada issued a Notice of Compliance for Taltz (ixekizumab), from Eli Lilly, injection, 80 mg/mL, for the treatment of pediatric patients from six to less than 18… read more.

Amgen submits supplemental NDA for Otezla for adults with mild-to-moderate plaque psoriasis

Written by | 1 Mar 2021

Amgen announced the submission of a supplemental New Drug Application (sNDA) to the FDA for Otezla (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are… read more.

Most psoriasis patients taking immunosuppressants survive COVID-19

Written by | 14 Nov 2020

Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19. According to the first findings from a global registry… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.